Company intelligence
uniQure
Transforming the lives of patients through gene therapy
Biotechnology Research
Amsterdam, NL
320 employees
Founded 1998
5 public signals
About uniQure
uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.
Verified activity
Signals from uniQure
5 published signals
Presence & Recognition
uniQure presented safety data related to the Fabry genetherapy trial at SSIEM 2026 in Helsinki, Finland
Reported by uniQure
Presence & Recognition
uniQure hosted its first-ever Visiting Professors Lecture at the Lexington office, featuring Dr. Kelly Andrzejewski and Dr. Jonathan Riley.
Reported by uniQure
Legal & Regulatory
uniQure submitted a Marketing Authorisation Application (MAA) for AMT-130 to the U.K.'s MHRA.
Reported by uniQure
Legal & Regulatory
uniQure submitted a BLA to the U.S. FDA for the accelerated approval of ifezuntirgene inilparvovec (AMT-130) for the treatment of Huntington's Disease.
Reported by uniQure
People
uniQure promoted Andrea Kocharyan to SVP, Commercial Law and Healthcare Compliance.
Reported by Andrea Kocharyan